Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3883593 | 0.98 | KDM4E (0.40) | TDP1KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL1304794 | 0.98 | KDM4E (0.40) | TDP1KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL3076471 | 0.98 | KDM4E (0.40) | TDP1KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL27842939 | 0.98 | KDM4E (0.40) | TDP1KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL3877421 | 0.98 | KDM4E (0.40) | TDP1KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL1756488 | 0.98 | KDM4E (0.40) | TDP1KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL20122066 | 0.98 | KDM4E (0.40) | TDP1KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL15791269 | 0.98 | KDM4E (0.40) | TDP1KDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL3870601 | 0.94 | KDM4E (0.42) | TDP1KDM4EALDH1A1HSD17B10MEN1 | |
| Ether SCHEMBL27805371 | 0.89 | KDM4E (0.35) | TDP1KDM4EALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920813-B | Photo-thermal response chiral photosensitive liquid crystal dopant containing azobenzene binaphthyl | 湘潭大学 | 2023-08-22 | — | — | CN | claimed |
| CN-112920813-A | Photo-thermal responsive chiral photosensitive liquid crystal dopant containing azobenzene binaphthalene | 湘潭大学 | 2021-06-08 | — | — | CN | claimed |
| CN-112920813-B | Photo-thermal response chiral photosensitive liquid crystal dopant containing azobenzene binaphthyl | 湘潭大学 | 2023-08-22 | — | — | CN | disclosed |
| US-11149203-B2 | Liquid crystal composition containing a five-membered heterocyclic ring, reverse-mode polymer dispersed liquid crystal element, and associated selectively dimmable device | NITTO DENKO CORPORATION (JP) | 2021-10-19 | — | — | US | disclosed |
| CN-112920813-A | Photo-thermal responsive chiral photosensitive liquid crystal dopant containing azobenzene binaphthalene | 湘潭大学 | 2021-06-08 | — | — | CN | disclosed |
| CN-111902519-A | Liquid crystal composition comprising five-membered heterocyclic ring, reverse mode polymer dispersed liquid crystal element and related selectively dimmable device | 日东电工株式会社 | 2020-11-06 | — | — | CN | disclosed |
| US-20200347302-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING A FIVE-MEMBERED HETEROCYCLIC RING, REVERSE-MODE POLYMER DISPERSED LIQUID CRYSTAL ELEMENT, AND ASSOCIATED SELECTIVELY DIMMABLE DEVICE | NITTO DENKO CORPORATION (JP) | 2020-11-05 | — | — | US | disclosed |
| WO-2019147842-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING A FIVE-MEMBERED HETEROCYCLIC RING, REVERSE-MODE POLYMER DISPERSED LIQUID CRYSTAL ELEMENT, AND ASSOCIATED SELECTIVELY DIMMABLE DEVICE | NITTO DENKO CORPORATION (JP) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019147842-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING A FIVE-MEMBERED HETEROCYCLIC RING, REVERSE-MODE POLYMER DISPERSED LIQUID CRYSTAL ELEMENT, AND ASSOCIATED SELECTIVELY DIMMABLE DEVICE | NITTO DENKO CORPORATION (JP) | 2019-08-01 | — | — | WO | disclosed |
| WO-2018152257-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING A FIVE-MEMBERED HETEROCYCLIC RING, REVERSE-MODE POLYMER DISPERSED LIQUID CRYSTAL ELEMENT, AND ASSOCIATED SELECTIVELY DIMMABLE DEVICE | NITTO DENKO CORPORATION (JP) | 2018-08-23 | — | — | WO | disclosed |
| EP-3227279-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | Eli Lilly and Company (US) | 2017-10-11 | — | — | EP | disclosed |
| WO-2016089670-A1 | 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS | ELI LILLY AND COMPANY (US) | 2016-06-09 | — | — | WO | disclosed |
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | DENOVAMED INC. (CA) | 2010-06-03 | — | — | US | disclosed |
| EP-1165721-B1 | LIQUID CRYSTALLINE ALKENYL COMPOUNDS INCORPORATING AN HETEROCYCLIC FIVE-MEMBERED RING | QINETIQ LTD (GB) | 2004-08-04 | — | — | EP | disclosed |
| US-6696110-B1 | THERMOGRAPHY | QINETIQ LIMITED (GB) | 2004-02-24 | — | — | US | disclosed |
| EP-1165721-A2 | LIQUID CRYSTALLINE ALKENYL COMPOUNDS INCORPORATING AN HETEROCYCLIC FIVE-MEMBERED RING | THE SECRETARY OF STATE FOR DEFENCE (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000060027-A2 | LIQUID CRYSTALLINE ALKENYL COMPOUNDS INCORPORATING AN HETEROCYCLIC FIVE-MEMBERED RING | QINETIQ LIMITED (GB) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137388-A1 | Therapeutic Pro-Antibiotic Agents and Methods of Use Thereof | NAT1, NAPEPLD, NR1I2 | TDP1 4183/4885KDM4E 3392/4885ALDH1A1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.